Catalyst Biosciences Joins the Russell 2000® Index
June 25 2018 - 08:30AM
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced it will join the
broad-market Russell 2000® Index at the conclusion of the
Russell US Indices annual reconstitution, which becomes effective
after the U.S. market opens on June 25, 2018.
The annual reconstitution of the Russell Indices
captures the 4,000 largest U.S. stocks as of May 11, 2018, ranking
them by total market capitalization. Membership in the Russell 2000
Index, which remains in place for one year, means automatic
inclusion in the Russell 3000® Index, as well as the
appropriate growth and value style indices. FTSE Russell determines
membership in the Russell US Indices primarily by objective,
market-capitalization rankings and style attributes.
“We are pleased to be added to the Russell 2000
Index and to receive the increased visibility within the
institutional investment community that comes with it,” said Nassim
Usman, Ph.D., chief executive officer of Catalyst. “We look forward
to expanding our shareholder base to include these important broad
based index funds.”
Russell US Indices are widely used by investment
managers and institutional investors as the basis for index funds
and as benchmarks for active investment strategies. Approximately
$9 trillion in assets are benchmarked against Russell US Indices.
Russell US Indices are part of the FTSE Russell, a leading global
index provider.
For more information on the Russell 2000 Index
and the Russell US Indices reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
About FTSE Russell:
FTSE Russell is a leading global index provider
creating and managing a wide range of indexes, data and analytic
solutions to meet client needs across asset classes, style and
strategies. Covering 98% of the investable market, FTSE Russell
indexes offer a true picture of global markets, combined with the
specialist knowledge gained from developing local benchmarks around
the world.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $16.2 trillion is currently benchmarked to FTSE
Russell indexes. For over 30 years, leading asset owners, asset
managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create investment funds, ETFs, structured products and index-based
derivatives. FTSE Russell indexes also provide clients with tools
for asset allocation, investment strategy analysis and risk
management.
A core set of universal principles guides FTSE
Russell index design and management: a transparent rules-based
methodology is informed by independent committees of leading market
participants. FTSE Russell is focused on index innovation and
customer partnership applying the highest industry standards and
embracing the IOSCO Principles. FTSE Russell is wholly owned by
London Stock Exchange Group.
For more information, visit www.ftserussell.com
About CatalystCatalyst is a
clinical-stage biopharmaceutical company developing novel medicines
to address hematology indications. Catalyst is focused on the field
of hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statement of historical facts (including, but not limited to,
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates”) are forward-looking
statements. Actual results or events could differ materially from
the plans, intentions, expectations and projections disclosed in
the forward-looking statements. Various important factors could
cause actual results or events to differ materially from the
forward-looking statements that the Company makes, including, but
not limited to, the risk that Catalyst will not remain in the
Russell 2000 Index or the Russell 3000 Index, that the Company’s
trials and studies may be delayed and may not have satisfactory
outcomes, that human trials will not replicate the results from
animal studies, that potential adverse effects may arise from the
testing or use of the Company’s products, including the generation
of antibodies, the risk that costs required to develop or
manufacture the Company’s products will be higher than anticipated,
competition and other factors that affect our ability to establish
collaborations on commercially reasonable terms and other risks
described in the “Risk Factors” section of the Company’s Annual
Report on Form 10-K for the year ended December 31, 2017 along with
other filings with the Securities and Exchange Commission. The
Company does not assume any obligation to update any
forward-looking statements, except as required by law.
Contacts
Investors:
Fletcher Payne,
CFO
Catalyst Biosciences,
Inc.
1.650.871.0761
investors@catbio.com
Media:Josephine Belluardo, Ph.D.LifeSci Public
Relations1.646.751.4361jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024